Nyrada, Inc. · ASX:NYR
Nyrada — Non-Deal Roadshow (June 2025)
23 slides from Nyrada's roadshow presentation, Jun 16, 2025
Slide 1: Non-Deal Investor Presentation
16 June 2025 Sydney, Australia Non-Deal Investor Presentation Nyrada Inc (ASX:NYR), a clinical stage drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors provides the enclosed investor presentation in connection with a non-
Slide 2: Investor Presentation June 2025
For personal use only Investor Presentation June 2025 Improving Lives, Offering Hope ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.
Slide 3: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any securities in NYR,
Slide 4: About Nyrada
About Nyrada For personal use only › Clinical stage drug discovery and development company focused on innovative small molecule Transient Receptor Potential Canonical (TRPC) ion channel inhibition. › Lead drug candidate Xolatryp (previously known as NYR-BI03) currently in Phase I safety and tolerabi
Slide 5: About Xolatryp
About Xolatryp › Third generation, small molecule TRPC ion For personal use only channel inhibitor developed using rational drug design. › Previously known as NYR-BI03. › Sound scientific foundation with underlying target proven in genetically modified mouse knock-out model. › Blocks TRPC 3, 6 and 7
Slide 6: Drug, Applications, Markets
One Two Three Drug Applications Markets For personal use only Xolatryp Neuroprotection STROKE ~US$52.2 billion by 20302 TRAUMATIC BRAIN INJURY ~US$5.5 billion by 20304 Cardioprotection MYOCARDIAL INFARCTION ~US$3.7 billion by 20325 5
Slide 7: About TRPC Channel Inhibition
About TRPC Channel Inhibition Activation following injury results For personal use only • in calcium entry via TRPC ion channels • Excessive calcium build-up leads to cell death • Inhibiting TRPC 3/6/7 ion channels is neuro- and cardio- protective Organ Cell Type TRPC Activation Effect Xolatryp Inhi
Slide 8: Phase I Clinical Trial
Phase I Clinical Trial Key Study Features For personal use only ✓ Primary Endpoints: ✓ safety and tolerability of Xolatryp healthy volunteers, when administered as an intravenous infusion for up to 6 hours ✓ Secondary Endpoints: ✓ blood pharmacokinetics of an intravenous dose of Xolatryp in healthy
Slide 9: Ischemic Stroke
Ischemic Stroke For personal use only › Statistically significant neuroprotection from secondary brain injury › MRI analysis undertaken by UNSW Sydney using a specialised technique known as fractional anisotropy (FA) to visualise structural damage in the penumbra. › 42% neuroprotection was seen in t
Slide 10: Traumatic Brain Injury (TBI)
Traumatic Brain Injury (TBI) For personal use only › Joint study with US Department of Defence (Walter Reed Army Institute of Research) and UNSW Sydney › Statistically significant neuroprotection 9
Slide 11: Myocardial Infarction (1)
Myocardial Infarction (1) Key Preclinical Results: Xolatryp showed strong For personal use only efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury • 86% Cardioprotection • 43% increase in left ventricular ejection fraction • 50% increase in fractional
Slide 12: Myocardial Infarction (2)
Myocardial Infarction (2) Key Preclinical Results: For personal use only Xolatryp showed strong efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion injury when administered as a short-duration intravenous infusion • 42% Cardioprotection • 88% decrease in arrhythmia
Slide 13: Conclusion
Conclusion › Summary For personal use only › Pioneering TRPC channel inhibition therapies. › Xolatryp Phase I (safety and tolerability) clinical trial well advanced › Xolatryp preclinical efficacy demonstrated in ischemic stroke, traumatic brain injury (TBI) and myocardial ischemia reperfusion injur
Slide 14: Key Market Announcements
Key Market Announcements › Phase I Clinical Trial For personal use only › Protocol Amendment – June 2024 › Cohort 3 Update – May 2024 › Ischemic Stroke › Preclinical Study – February 2024 › Traumatic Brain Injury (TB() › Preclinical Study – April 2025 › Acute Myocardia Ischemia › Preclinical Study –
Slide 15: Appendices
For personal use only Appendices 14
Slide 16: Vision and Strategy
Vision and Strategy For personal use only Our Vision: • to become a high-growth pharmaceutical company specialising in the discovery and development of novel treatments Our Strategy: • to develop treatments for diseases where there is an unmet clinical need, or where current treatments are suboptima
Slide 17: Large Market Opportunity – Myocardial Infarction
Large Market Opportunity – Myocardial Infarction For personal use only Globally: ~15-20 million ~15% people suffer heart mortality within 30 attack annually days No current FDA approved treatments targeting myocardial infarction-reperfusion injury Effective treatment will improve patient outcomes an
Slide 18: Large Market Opportunity – Stroke
Large Market Opportunity – Stroke For personal use only Globally: ~15 million ~5 million people suffer left permanently strokes annually1 disabled1 One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator). Effective treatment will improve patient outcomes
Slide 19: Large Market Opportunity – Traumatic Brain Injury (TBI)
Large Market Opportunity – Traumatic Brain Injury (TBI) For personal use only Globally: ~5.5 million ~55 million people suffer severe living with effects of TBA annually3 medically treated TBI3 No current FDA approved treatments Effective treatment will improve patient outcomes and reduce high costs
Slide 20: Neuroprotection – Stroke and TBI
Neuroprotection – Stroke and TBI Serial reconstruction from MRI For personal use only Secondary Disability Primary Injury Injury Level 30 mins BECAME STAYED THE DIED WORSE SAME IMPROVED 72 hours Hours Days Weeks Months Reduce secondary injury resulting from stroke or TBI Nyrada drug Xolatryp • Impro
Slide 21: Drug Development Cycle
Drug Development Cycle For personal use only Discovery & Preclinical Clinical FDA Post-market Development research trials review safety monitoring Scientists study how Once promising If the compounds After clinical trials, After a drug is a disease affects compounds are pass preclinical tests, the c
Slide 22: References
References 1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular- For personal use only accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20i s%20high%20blood%20pressure 2 – Databridge Market Research - https://www.databridgemar
Slide 23: For personal use only
For personal use only @nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 22